Revisiting the Incidence of Tardive Dyskinesia With Oral Metoclopramide Use: A Real‐World Epidemiology Study (2011–2020)

Key Points

Uncommon incidence of tardive dyskinesia is observed with metoclopramide use, indicating it may be a safer option.
Evidence shows TD incidence is lower than previously estimated in instances of gastroparesis treatment.
Analysis using real-world data from 2011 to 2020 provides a contemporary perspective on TD risk with metoclopramide.
Highlights the need to reassess the risk-benefit profile of metoclopramide in managing gastroparesis patients.

Abstract

TD incidence is uncommon with metoclopramide use and lower than previously estimated in gastroparesis patients. These findings suggest metoclopramide may be a viable treatment option and warrant a reassessment of its risk-benefit profile in gastroparesis management.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

McCallum et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75abdc6e9836116a20f06 https://doi.org/https://doi.org/10.1111/nmo.70206

Bookmark

View Full Paper